Tirzepatide
Dual GIP/GLP-1 agonist — the leading edge of metabolic research.
Tirzepatide
Background
Tirzepatide is a synthetic 39-amino-acid peptide that functions as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By engaging both incretin pathways simultaneously, it has been studied for enhanced effects on insulin secretion, satiety, and body-weight regulation relative to selective GLP-1 agonists.
The SURPASS program (type 2 diabetes) and SURMOUNT program (obesity) constitute a large, high-quality randomized controlled evidence base, including a head-to-head trial against semaglutide that reported greater reductions in HbA1c and body weight.
Selected literature
- Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503-515.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
- Rosenstock J, et al. Efficacy and safety of tirzepatide monotherapy (SURPASS-1). The Lancet. 2021;398(10295):143-155.
References are provided for scientific context only. Citation does not imply endorsement of any use, nor a claim of safety or efficacy. Findings frequently derive from in-vitro or animal models.
Trademarks & attribution
Tirzepatide is the active ingredient marketed as Mounjaro(R) and Zepbound(R) by Eli Lilly and Company. Those trademarks are the property of Eli Lilly and Company. Catalyst Research Labs is not affiliated with, endorsed by, or sponsored by Eli Lilly. Supplied as reference material only.
